Massey researcher selected as national leader for large-scale NCI clinical trial
Known as the NCI-MATCH trial – National Cancer Institute Molecular Analysis for Therapy Choice Program, the study will consist of numerous small, phase 2 trials that will examine solid tumors and lymphomas that no longer respond to standard treatment and have begun to grow. Next-generation DNA sequencing will be administered on tumor biopsies from as many as 3,000 patients nationwide to determine the cell’s “broken” mechanism and, therefore, what is causing the cancer growth.
Massey researchers identify patients at risk for stem cell transplant complications
Researchers at VCU Massey Cancer Center’s Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival. This first-of-its-kind research continues the efforts of principal investigator Amir Toor, M.D., to understand the immune system as a dynamical system that can be modeled to improve stem cell transplantation.
Common antibiotic part of a promising potential pancreatic cancer therapy
Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.
Koblinski joins Massey as a research member
Massey welcomes Jennifer Koblinski, Ph.D., as a research member in the Cancer Molecular Genetics program. Koblinski joined the VCU Department of Pathology as an assistant professor in 2013. Koblinski’s primary research interest focuses on the mechanisms that facilitate breast cancer metastasis to the brain.
Massey researcher leads team to improve data reporting of meningioma treatment outcomes nationwide
A new study led by VCU Massey Cancer Center physician-researcher Leland Rogers, M.D., found that clinical trials to treat the most common primary brain tumor, meningioma, lack uniform guidelines for how physicians should determine whether treatment is effective at shrinking the tumor. The study was published in the Journal of Neurosurgery.